FOXR1

Summary

FOXR1 (forkhead box R1, HGNC:29980) is a protein-coding gene on chromosome 11q23.3, encoding Forkhead box protein R1 (Q6PIV2). Transcription factor which acts as both an activator and a repressor.

This gene encodes a member of the forkhead box (FOX) family of transcription factors. FOX family members are monomeric, helix-turn-helix proteins with a core DNA-binding domain of approximately 110 aa. Many FOX transcription factors play roles in determining cell fates during early development. This forkhead box protein lacks the C-terminal basic region found in many other FOX family members. It is located within the 11q23.3 region which is commonly deleted in neuroblastomas.

Source: NCBI Gene 283150 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Moderate, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 51 total — 1 pathogenic
• MANE Select transcript: NM_181721

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29980
Approved symbol	FOXR1
Name	forkhead box R1
Location	11q23.3
Locus type	gene with protein product
Status	Approved
Aliases	DLNB13, FOXN5
Ensembl gene	ENSG00000176302
Ensembl biotype	protein_coding
OMIM	615755
Entrez	283150

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding, 1 nonsense_mediated_decay

ENST00000317011, ENST00000531539, ENST00000533282

RefSeq mRNA: 1 — MANE Select: NM_181721 NM_181721

CCDS: CCDS31688

Canonical transcript exons

ENST00000317011 — 6 exons

Exon	Start	End
ENSE00001276040	118979442	118979668
ENSE00001276048	118978957	118979204
ENSE00001276055	118978782	118978856
ENSE00001290808	118971761	118971992
ENSE00001609855	118980490	118980728
ENSE00001711462	118981208	118981287

Expression profiles

Bgee: expression breadth broad, 50 present calls, max score 87.80.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0075 / max 3.5827, expressed in 4 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
117077	0.0075	4

Top tissues by expression

86 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.80	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.79	gold quality
right testis	UBERON:0004534	67.98	gold quality
testis	UBERON:0000473	67.90	gold quality
left testis	UBERON:0004533	67.58	gold quality
cortical plate	UBERON:0005343	51.52	gold quality
ganglionic eminence	UBERON:0004023	42.46	gold quality
bone marrow cell	CL:0002092	38.35	gold quality
colonic epithelium	UBERON:0000397	37.20	gold quality
prefrontal cortex	UBERON:0000451	36.91	gold quality
ventricular zone	UBERON:0003053	36.48	gold quality
mucosa of transverse colon	UBERON:0004991	35.63	gold quality
right ovary	UBERON:0002118	35.07	gold quality
skeletal muscle tissue	UBERON:0001134	34.87	gold quality
bone marrow	UBERON:0002371	34.82	silver quality
fundus of stomach	UBERON:0001160	33.97	gold quality
frontal cortex	UBERON:0001870	33.76	gold quality
hypothalamus	UBERON:0001898	32.86	silver quality
Brodmann (1909) area 9	UBERON:0013540	32.47	gold quality
cerebral cortex	UBERON:0000956	32.33	gold quality
muscle tissue	UBERON:0002385	32.15	gold quality
hindlimb stylopod muscle	UBERON:0004252	32.15	gold quality
ovary	UBERON:0000992	31.99	gold quality
right coronary artery	UBERON:0001625	31.78	silver quality
lymph node	UBERON:0000029	31.38	gold quality
urinary bladder	UBERON:0001255	31.33	gold quality
skin of leg	UBERON:0001511	31.33	silver quality
anterior cingulate cortex	UBERON:0009835	31.16	silver quality
dorsolateral prefrontal cortex	UBERON:0009834	31.15	silver quality
zone of skin	UBERON:0000014	31.00	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.27

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 3)

• FOXR1 is recurrently activated in neuroblastoma by intrachromosomal deletion/fusion events, resulting in overexpression of fusion transcripts (PMID:21860421)
• FOXR1 expression is activated by chromosome 11q23 aberrations in B-cell lymphoma. (PMID:27284737)
• FOXR1 regulates stress response pathways and is necessary for proper brain development. (PMID:34723967)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Foxr1	ENSMUSG00000074397
rattus_norvegicus	Foxr1	ENSRNOG00000029089

Paralogs (41): FOXP3 (ENSG00000049768), FOXC1 (ENSG00000054598), FOXJ2 (ENSG00000065970), FOXF1 (ENSG00000103241), FOXN1 (ENSG00000109101), FOXM1 (ENSG00000111206), FOXP1 (ENSG00000114861), FOXO3 (ENSG00000118689), FOXA2 (ENSG00000125798), FOXA1 (ENSG00000129514), FOXJ1 (ENSG00000129654), FOXK2 (ENSG00000141568), FOXO1 (ENSG00000150907), FOXH1 (ENSG00000160973), FOXQ1 (ENSG00000164379), FOXK1 (ENSG00000164916), FOXD4 (ENSG00000170122), FOXA3 (ENSG00000170608), FOXB1 (ENSG00000171956), FOXL1 (ENSG00000176678), FOXC2 (ENSG00000176692), FOXE1 (ENSG00000178919), FOXS1 (ENSG00000179772), FOXL2 (ENSG00000183770), FOXO4 (ENSG00000184481), FOXD4L1 (ENSG00000184492), FOXD4L4 (ENSG00000184659), FOXD2 (ENSG00000186564), FOXI2 (ENSG00000186766), FOXE3 (ENSG00000186790), FOXD3 (ENSG00000187140), FOXD4L3 (ENSG00000187559), FOXR2 (ENSG00000189299), FOXJ3 (ENSG00000198815), FOXO6 (ENSG00000204060), FOXB2 (ENSG00000204612), FOXD4L5 (ENSG00000204779), FOXI3 (ENSG00000214336), FOXL3 (ENSG00000248767), FOXD1 (ENSG00000251493)

Protein

Protein identifiers

Forkhead box protein R1 — Q6PIV2 (reviewed: Q6PIV2)

Alternative names: Forkhead box protein N5

All UniProt accessions (2): Q6PIV2, H0YCU3

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor which acts as both an activator and a repressor. Activates transcription of a number of genes including the heat shock chaperones HSPA1A and HSPA6 and the antioxidant NADPH-dependent reductase DHRS2 which are involved in protection against oxidative stress. Required for normal brain development.

Subcellular location. Nucleus. Cytoplasm. Perinuclear region.

Tissue specificity. Expressed in testis (at protein level).

Disease relevance. Defects in FOXR1 may be the cause of a severe neurological disorder characterized by postnatal microcephaly, progressive brain atrophy and global developmental delay.

Induction. Induced by cellular stress.

Isoforms (2)

UniProt ID	Names	Canonical?
Q6PIV2-1	1	yes
Q6PIV2-2	2

RefSeq proteins (1): NP_859072* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001766	Fork_head_dom	Domain
IPR036388	WH-like_DNA-bd_sf	Homologous_superfamily
IPR036390	WH_DNA-bd_sf	Homologous_superfamily
IPR052328	FOX_transcription_regulators	Family

Pfam: PF00250

UniProt features (13 total): compositionally biased region 5, splice variant 2, region of interest 2, chain 1, DNA-binding region 1, sequence variant 1, mutagenesis site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6PIV2-F1	67.06	0.27

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (1):

Position	Phenotype
280–292	reduced protein expression and formation of nuclear puncta in some cells.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 26 (showing top): GOBP_HEAD_DEVELOPMENT, HSF2_01, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II, GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II, KUMAR_PATHOGEN_LOAD_BY_MACROPHAGES, GOMF_DNA_BINDING_TRANSCRIPTION_ACTIVATOR_ACTIVITY, GOMF_DNA_BINDING_TRANSCRIPTION_REPRESSOR_ACTIVITY, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, HMGA1_TARGET_GENES, GOBP_POSITIVE_REGULATION_OF_RNA_METABOLIC_PROCESS, GOMF_DNA_BINDING_TRANSCRIPTION_FACTOR_ACTIVITY, JONES_OVARY_OOCYTE, GOBP_NEGATIVE_REGULATION_OF_RNA_BIOSYNTHETIC_PROCESS

GO Biological Process (5): regulation of transcription by RNA polymerase II (GO:0006357), brain development (GO:0007420), positive regulation of transcription by RNA polymerase II (GO:0045944), negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (8): DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677), DNA-binding transcription factor activity (GO:0003700), protein binding (GO:0005515), sequence-specific DNA binding (GO:0043565)

GO Cellular Component (4): chromatin (GO:0000785), nucleus (GO:0005634), cytoplasm (GO:0005737), perinuclear region of cytoplasm (GO:0048471)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase II	3
regulation of transcription by RNA polymerase II	3
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
cellular anatomical structure	3
regulation of DNA-templated transcription	2
DNA-binding transcription factor activity, RNA polymerase II-specific	2
central nervous system development	1
animal organ development	1
head development	1
positive regulation of DNA-templated transcription	1
negative regulation of DNA-templated transcription	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
chromatin	1
DNA-binding transcription factor activity	1
negative regulation of transcription by RNA polymerase II	1
DNA-binding transcription repressor activity	1
DNA-binding transcription activator activity	1
positive regulation of transcription by RNA polymerase II	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
nucleic acid binding	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
binding	1
DNA binding	1
chromosome	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

718 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FOXR1	PAFAH1B2	P68402	506
FOXR1	UPK2	O00526	465
FOXR1	RNF26	Q9BY78	452
FOXR1	FAM187A	A6NFU0	452
FOXR1	RPS25	P25111	414
FOXR1	CENATAC	Q86UT8	393
FOXR1	PHLDB1	Q86UU1	391
FOXR1	BCL9L	Q86UU0	369
FOXR1	FOXP4	Q8IVH2	366
FOXR1	TEX9	Q8N6V9	342
FOXR1	SPMIP5	Q8WW14	342
FOXR1	A0A3B3IT14	A0A3B3IT14	335
FOXR1	C2CD2L	O14523	327
FOXR1	ZAR1	Q86SH2	325
FOXR1	POU6F2	P78424	323

IntAct

91 interactions, top by confidence:

A	B	Type	Score
PPCDC	FOXR1	psi-mi:“MI:0915”(physical association)	0.780
FOXR1	PPCDC	psi-mi:“MI:0915”(physical association)	0.780
FOXR1	YEATS4	psi-mi:“MI:0914”(association)	0.640
FOXR1	MEOX2	psi-mi:“MI:0915”(physical association)	0.560
FOXR1	FLJ13057	psi-mi:“MI:0915”(physical association)	0.560
FOXR1	BANP	psi-mi:“MI:0915”(physical association)	0.560
BANP	FOXR1	psi-mi:“MI:0915”(physical association)	0.560
FOXR1	CEP19	psi-mi:“MI:0915”(physical association)	0.560
FOXR1	DPPA4	psi-mi:“MI:0915”(physical association)	0.560
FOXR1	GMCL1	psi-mi:“MI:0915”(physical association)	0.560
FOXR1	A2M	psi-mi:“MI:0915”(physical association)	0.560
FOXR1	APBB2	psi-mi:“MI:0915”(physical association)	0.560
FOXR1	DMWD	psi-mi:“MI:0915”(physical association)	0.560
FOXR1	DNM2	psi-mi:“MI:0915”(physical association)	0.560
FOXR1	TOR1A	psi-mi:“MI:0915”(physical association)	0.560
FOXR1		psi-mi:“MI:0915”(physical association)	0.560
FOXR1	MECP2	psi-mi:“MI:0915”(physical association)	0.560
FOXR1	PMP22	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (94): FOXR1 (Two-hybrid), FOXR1 (Two-hybrid), FOXR1 (Two-hybrid), FOXR1 (Two-hybrid), EP400 (Affinity Capture-MS), MEAF6 (Affinity Capture-MS), EPC1 (Affinity Capture-MS), EPC2 (Affinity Capture-MS), DMAP1 (Affinity Capture-MS), TRRAP (Affinity Capture-MS), SULT1A1 (Affinity Capture-MS), BRD8 (Affinity Capture-MS), VPS72 (Affinity Capture-MS), ING3 (Affinity Capture-MS), MYC (Affinity Capture-MS)

ESM2 similar proteins: A1A4L6, A2CI98, A2CJ06, O09139, O35254, O94966, O95238, P0C6P5, P15036, P15037, P19102, P59729, P78545, P97433, Q01094, Q14209, Q28F43, Q2KHT9, Q3UPW2, Q3UTB7, Q4V7E1, Q5EB20, Q5PQS0, Q5XIS1, Q61501, Q66IG8, Q6DGF9, Q6NZK8, Q6P1I6, Q6PIV2, Q6ZTZ1, Q76I79, Q7TSI1, Q80U38, Q8BLR5, Q8IUY3, Q8K330, Q8NC06, Q8TB24, Q8TE77

Diamond homologs: A0A078BQN7, A0A1W2PRP0, A0A8V0YY16, A1L1S5, A3KNJ3, A8MTJ6, A8XJN7, B5RHS5, D3Z120, F1R8Z9, O00358, O17617, O43638, O54743, O60129, O88470, P32027, P32028, P32030, P32315, P42128, P55316, P56260, P58012, P79772, P85037, P91278, Q00939, Q01167, Q02360, Q12946, Q12947, Q12948, Q12950, Q12951, Q12952, Q13461, Q19802, Q1A1A1, Q1A1A2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

51 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	42
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
253520	GRCh37/hg19 11q23.3(chr11:115215434-120559928)x3	Pathogenic

SpliceAI

960 predictions. Top by Δscore:

Variant	Effect	Δscore
11:118971988:GAAAC:G	donor_gain	1.0000
11:118971989:AAACG:A	donor_loss	1.0000
11:118971990:AAC:A	donor_gain	1.0000
11:118971991:AC:A	donor_gain	1.0000
11:118971991:ACGTG:A	donor_loss	1.0000
11:118971993:G:GG	donor_gain	1.0000
11:118979171:G:GT	donor_gain	1.0000
11:118971989:AAAC:A	donor_gain	0.9900
11:118971994:T:A	donor_loss	0.9900
11:118978780:A:AG	acceptor_gain	0.9900
11:118978781:G:GA	acceptor_gain	0.9900
11:118978852:GGATG:G	donor_gain	0.9900
11:118978853:GATGG:G	donor_gain	0.9900
11:118979200:GGGAG:G	donor_gain	0.9900
11:118979201:GGAGG:G	donor_gain	0.9900
11:118979202:G:GT	donor_gain	0.9900
11:118979202:G:T	donor_gain	0.9900
11:118979205:G:C	donor_loss	0.9900
11:118979440:A:AG	acceptor_gain	0.9900
11:118979441:G:GG	acceptor_gain	0.9900
11:118980488:A:AG	acceptor_gain	0.9900
11:118980489:G:GG	acceptor_gain	0.9900
11:118980489:GAAA:G	acceptor_gain	0.9900
11:118980699:A:T	donor_gain	0.9900
11:118978780:AGTT:A	acceptor_gain	0.9800
11:118978781:GTTG:G	acceptor_gain	0.9800
11:118978955:A:AG	acceptor_gain	0.9800
11:118978956:G:GG	acceptor_gain	0.9800
11:118979015:T:TA	acceptor_gain	0.9800
11:118979201:GGAG:G	donor_gain	0.9800

AlphaMissense

1911 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:118980527:T:A	W217R	0.997
11:118980527:T:C	W217R	0.997
11:118980529:G:C	W217C	0.996
11:118980529:G:T	W217C	0.996
11:118980569:T:C	F231L	0.996
11:118980571:T:A	F231L	0.996
11:118980571:T:G	F231L	0.996
11:118980631:G:C	W251C	0.996
11:118980631:G:T	W251C	0.996
11:118980540:T:A	V221D	0.995
11:118979661:T:C	F202L	0.994
11:118979663:C:A	F202L	0.994
11:118979663:C:G	F202L	0.994
11:118980497:T:C	F207L	0.994
11:118980499:C:A	F207L	0.994
11:118980499:C:G	F207L	0.994
11:118980506:T:C	F210L	0.994
11:118980508:C:A	F210L	0.994
11:118980508:C:G	F210L	0.994
11:118980532:G:C	K218N	0.994
11:118980532:G:T	K218N	0.994
11:118980545:C:G	H223D	0.994
11:118980629:T:A	W251R	0.994
11:118980629:T:C	W251R	0.994
11:118980547:C:A	H223Q	0.992
11:118980547:C:G	H223Q	0.992
11:118980503:T:C	F209L	0.991
11:118980505:T:A	F209L	0.991
11:118980505:T:G	F209L	0.991
11:118980507:T:C	F210S	0.991

dbSNP variants (sampled 300 via entrez): RS1000345189 (11:118971596 C>G), RS1000420406 (11:118971298 CAG>C), RS1000536717 (11:118972756 T>C), RS1000639502 (11:118977824 C>A,T), RS1001220690 (11:118972619 T>C), RS1001327972 (11:118978565 A>C), RS1001534223 (11:118972210 TG>T,TGG), RS1001908013 (11:118979506 A>C,G), RS1001963865 (11:118971825 TCCGCGCCG>T,TCCGCGCCGCCGCGCCG), RS1002034547 (11:118973253 A>G), RS1002041028 (11:118973541 A>G), RS1002335717 (11:118977096 T>A), RS1002711784 (11:118976488 C>T), RS1003171334 (11:118981013 A>T), RS1003251776 (11:118973430 T>C)

Disease associations

OMIM: gene MIM:615755 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Moderate	Autosomal dominant

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST009798_24	Asthma	4.000000e-11

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

5 total (human), top 5 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Arsenic	affects methylation	1
Cadmium	decreases expression, increases abundance	1
Silicon Dioxide	decreases expression	1
8-Bromo Cyclic Adenosine Monophosphate	increases expression	1
Cadmium Chloride	decreases expression, increases abundance	1

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice